|
A |
B |
C |
08:00-09:00 |
Registration |
09:00-0910 |
Opening remarks : ÇÐȸÀå |
09:10-10:00 |
Symposium I : safety of living donors |
10:00-11:00 |
Plenary lecture
Safety of living organ donors |
11:00-11:20 |
Coffee break |
11:20-12:30 |
Symposium II: Updates in Transplantation Related Infection |
12:30-12:50 |
General assembly |
12:50-13:50 |
Luncheon Symposium |
13:50-14:00 |
Break |
14:00-15:15 |
Concurrent symposium I
Kidney Transplanation |
Concurrent symposium II
Liver Transplanation |
Concurrent symposium III
Pathology and diagnostic immunology |
15:15-15:30 |
Coffee break |
15:30-16:45 |
Concurrent symposium IV
Kidney Transplanation |
Concurrent symposium V
Liver Transplanation |
Concurrent symposium VI
Coordinator Session |
|
³»¿ë |
ÁÂÀå/¿¬ÀÚ |
9:00~9:10 |
Opening |
Symposium I :
Safety of Living Donors |
ÁÂÀå: Á¶¿øÇö (°è¸íÀÇ´ë),
ÀÌ½Â±Ô (¿ï»êÀÇ´ë) |
9:10~9:35 |
»ýü ½ÅÀåÀÌ½Ä °ø¿©ÀÚÀÇ ¾ÈÁ¤¼º |
ÃÖ¼öÁø³ª (Àü³²ÀÇ´ë) |
9:35~10:00 |
»ýü °£ÀÌ½Ä °ø¿©ÀÚÀÇ ¾ÈÁ¤¼º |
Ȳ ½Å (¿ï»êÀÇ´ë) |
Plenary Lecture :
Safety of Living Organ Donors |
ÁÂÀå: ±èÇöö (°è¸íÀÇ´ë) |
10:00~11:00 |
Donor safety in living donor kidney transplantation |
Gabriel Danovitch(UCLA) |
11:00~11:20 |
Coffee Break |
Symposium II :
Updates in Transplantation Related Infection |
ÁÂÀå: ÇÑ´öÁ¾ (¿ï»êÀÇ´ë),
±è¼®¿µ (°¡Å縯ÀÇ´ë) |
11:20~11:37 |
Fever, Friend or Foe? |
±è»óÀÏ (°¡Å縯ÀÇ´ë) |
11:37~11:54 |
Superbacteria, Are there Treatment Options? |
¹é°æ¶õ (¼º±Õ°üÀÇ´ë) |
11:55~12:12 |
Emerging Viral Infection in Transplanted patients |
¹Ú¿Ï¹ü (¼¿ïÀÇ´ë) |
12:12~12:29 |
New Diagnostic Methods in Transplant infection |
¿ëµ¿Àº (¿¬¼¼ÀÇ´ë) |
12:30-12:50 |
ÀÓ½ÃÃÑȸ |
Luncheon Symposium (Genzyme) |
ÁÂÀå: ÇÑ´öÁ¾(¿ï»êÀÇ´ë) |
12:50~13:50 |
Recent updates in Kidney Transplantation induction wity Thymoglobuline |
Tatsuo Kawai(Harvard Medical School) |
13:50-14:00 |
Break |
Concurrent Symposium I:
Kidney 1-Kidney transplantation and age |
ÁÂÀå: ¾È±Ô¸®(¼¿ïÀÇ´ë),
¹®Àμº(°¡Å縯ÀÇ´ë) |
14:00~14:25 |
Kidney Transplantation to old Recipients |
ÀÌ ½Ä(ÀüºÏÀÇ´ë) |
14:25~14:50 |
Kidney transplantation from old Donors |
¿Àâ±Ç(¾ÆÁÖÀÇ´ë) |
14:50~15:15 |
Current issues in Pediatric Kidney Transplantation |
°Èñ°æ (¼¿ïÀÇ´ë) |
Concurrent Symposium II:
Liver 1-ABO-incompatible liver transplantation |
ÁÂÀå: À̼®±¸ (¼º±Õ°üÀÇ´ë),
¿ÕÈñÁ¤ (¾ÆÁÖÀÇ´ë) |
14:00~14:25 |
Action Mechanism of Rituximab |
±èÅÂÁø (¼º±Õ°üÀÇ´ë) |
14:25~14:50 |
Role of Plasma Exchange |
±Ç¼®¿î (¿ï»êÀÇ´ë) |
14:50~15:15 |
Practical Institutional Protocols |
¼Û±â¿ø (¿ï»êÀÇ´ë) |
Concurrent Symposium III:
Pathology and Diagnostic immunology :
Recent advances in the diagnosis of renal transplant rejection |
ÁÂÀå: Á¤»ó¿µ (Àü³²ÀÇ´ë),
Á¤ÇöÁÖ (¿¬¼¼ÀÇ´ë) |
14:00~14:25 |
C4d and Acute Antibody Mediated Rejection |
ÃÖ¿µÁø (°¡Å縯ÀÇ´ë) |
14:25~14:50 |
C4d and Chronic Antibody Mediated Rejection |
ÀÓ¹üÁø (¿¬¼¼ÀÇ´ë) |
14:50~15:15 |
Reevaluation of Chronic Allograft Nephropathy |
Áø¼Ò¿µ (¼øõÇâÀÇ´ë) |
15:15-15:30 |
Coffee Break |
Concurrent Symposium IV:
Kidney 2-Debate for choice of immunosuppressants in living donor kidney transplantation |
ÁÂÀå: ±èÀ¯¼± (¿¬¼¼ÀÇ´ë),
±Ç¿ÀÁ¤ (ÇѾçÀÇ´ë) |
15:30~15:55 |
Tacrolimus vs. Cyclosporine |
±èÁß°æ(ºÀ»ýº´¿ø) |
15:55~16:20 |
Mycophenolate vs. azathioprine/no anti-proliferative agent |
Á¶È«·¡(¿ï»êÀÇ´ë) |
16:20~16:45 |
Role of mTOR inhibitors |
¾çö¿ì(°¡Å縯ÀÇ´ë) |
Concurrent Symposium V:
Liver 2 - Renal dysfunction before and after liver transplantation |
ÁÂÀå: ±èµ¿±¸(°¡Å縯ÀÇ´ë),
±è¼øÀÏ(¿¬¼¼ÀÇ´ë) |
15:30~15:55 |
Management of hepatorenal syndrome |
Á¶Àç¿ø (¼º±Õ°üÀÇ´ë) |
15:55~16:20 |
Treatment of early posttransplant renal dysfunction |
À̳²ÁØ (¼¿ïÀÇ´ë) |
16:20~16:45 |
Prevention of long-term nephrotoxicity |
±è¸í¼ö (¿¬¼¼ÀÇ´ë) |
Concurrent Symposium VI:
Coordinator -Transplantation in high immunological risk recipient |
ÁÂÀå: Àü°æ¿Á (¼¼ºê¶õ½ºº´¿ø),
º¹ÃáÈñ (Çѱ¹Àå±â±âÁõ¿ø) |
15:30~15:55 |
Positive crossmatch ȯÀÚÀÇ ½ÅÀåÀÌ½Ä |
±èÂù´ö(°æºÏÀÇ´ë) |
15:55~16:20 |
ABO incompatible KTx |
±èº´Ã¢ (¸Þ¸®³îº´¿ø) |
16:20~16:45 |
ABO incompatible LTx |
Á¤µ¿È¯ (¿ï»êÀÇ´ë) |